Study on clinical significance of different subgroups of irritable bowel syndrome patients in Zhejiang province
Liang-jing WANG,Shu-jie CHEN,Jian-min SI
DOI: https://doi.org/10.3969/j.issn.1672-2159.2003.02.008
2003-01-01
Abstract:Objective To evaluate the clinical characteristics of irritable bowel syndrome (IBS) subgroups in Zhejiang province, and discuss the significance of this clinical typing in Chinese IBS patients. Methods From January 2001 to January 2002, 540 consecutive Roma Ⅱ criteria- positive IBS patients were evaluated by gastroenterologists from Digestive Disease Center in Zhejiang province (DDCZ). Patients were classified to three subgroups as constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and alternating constipation and diarrhea IBS (IBS-A) according to the predominant bowel habit. All patients completed the demographic checklists, symptoms questionnaire and quality of life (QoL) by Chinese version of the SF-36. 126 patients were voluntarily assigned to 8-week therapies with Pinaverium bromide (100 mg three times daily). Results IBS-C and IBS-A were more common in female patients, whereas male patients experienced more cases of IBS-D (P0.01). More IBS-D patients had drinking habitas compared with IBS-C patients (P0.05). More IBS-D patients were smokersas compared with IBS-A patients(P0.05). There were no significant differences in age distribution among three IBS subgroups(P0.05); (2) IBS consisted of IBS-D (47.8 %), IBS-A(32.2%) and IBS-C(20.0 %), respectively. In regards to the IBS predominant bowel symptoms, there were significant differences among IBS subgroups. Abdominal pain (frequency2 days per week and duration1 hour per day) were more frequent in IBS-A patients , while IBS-D patients more frequently experienced of passage of mucus, dyspeptic symptoms and anxiety(P0.05); (3) The QoL in three subgroup was impaired in vitality, general health and mental health. Compared with IBS-D, QoL in IBS-C scored significantly lower on physical function, role emotion, general health and mental health scales (P0.05); (4) The total symptom improvement rate and symptom remission rate were achieved by 60.8 % and 30.4 % in IBS-C patients, and 94.9% and 57.6% in IBS-D patients, while 77.3% and 59.1% in IBS-A patients, respectively. Few IBS-C patients noted symptom remission than IBS-D and IBS-A (P0.05). Conclusion There are different demographic characteristics, clinical symptoms, quality of life and symptom efficacy among the three IBS subgroups.